Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a. 
Long non-coding RNA cancer susceptibility candidate 2 (CASC2) is a novel lncRNA and has been indicated as playing tumour suppressor gene in several tumours.  However, the role of CASC2 in osteosarcoma is still uncovered.  The CASC2 and miR-181a expressions were measured via qRT-PCR.  CCK-8 assay and colony formation assay were performed to determine the cell growth, and transwell assay was performed to assess the cell invasion.  We showed that CASC2 expression was downregulated in osteosarcoma samples and cell lines.  Moreover, we showed that downregulated expression of CASC2 was correlated with advanced TNM stage.  Furthermore, overexpression of CASC2 inhibited osteosarcoma cell proliferation, colony formation, and invasion.  In addition, we indicated that ectopic expression of CASC2 suppressed miR-181a expression and enhanced the expression of Ras association domain family member 6 (RASSF6), PTEN and ATM in osteosarcoma cell, which were the direct target gene of miR-181a.  Moreover, we indicated that RASSF6 expression was downregulated in osteosarcoma samples and cell lines and downregulated expression of RASSF6 was correlated with advanced TNM stage.  We found that the expression of RASSF6 was positively correlated with the expression of CASC2 in osteosarcoma tissues.  Ectopic expression of CASC2 suppressed the osteosarcoma cell proliferation, colony formation and invasion through regulating RASSF6 expression.  Our data illuminated that CASC2 acted as a tumour suppressor in osteosarcoma progression.